Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

PP405 shows promise in reactivating dormant hair follicles, with early trials indicating some success, but it is not yet a proven treatment for hair loss. Users are advised to be cautious with unverified versions, and further research is needed to confirm its effectiveness compared to treatments like minoxidil and finasteride.

Minoxidil and finasteride are the only FDA-approved treatments for androgenetic alopecia, while newer treatments like clascoterone, PP405, NV-623/624, AMP-303, and RU58841 are still experimental with varying levels of evidence. Clascoterone shows the most promise due to strong human data, while AMP-303 has notable early human trial results; RU58841 lacks human data and remains experimental.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

Hair loss treatments are being tested on mice, with methods like minoxidil and stem cell therapy showing promising results. However, human trials are still years away, leading to humorous frustration about mice benefiting first.

A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.

New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.

PP405 and hair cloning are discussed as potential treatments for reversing hair loss from Norwood 7 to Norwood 1. Hair cloning is seen as a more permanent solution, while PP405's effectiveness and long-term effects remain uncertain.

PP405 significantly improves hair density, outperforming finasteride, with 31% of users seeing over 20% improvement in four weeks. Concerns exist about its availability, cost, and long-term effects.

The user is experiencing hair regrowth using oral minoxidil, finasteride, dermastamping, and ketoconazole shampoo. Suggestions include adding pyrilutamide or considering dutasteride instead of finasteride.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

A user is seeking a titanium dioxide-free finasteride pill due to health concerns. They have not found a suitable supplier yet.

He Shou Wu (Fo Ti) extract was found to prolong the hair growth phase, inhibit 5-alpha-reductase (like finasteride), reduce androgen receptors, and increase growth factors, potentially outperforming minoxidil in recovering hair follicle size after DHT exposure. Two compounds, emodin and TSG, are identified as responsible for these effects and warrant further investigation.

A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.

The conversation discusses a hair loss treatment formulation containing cyclosporin, minoxidil, and tacrolimus, and mentions ongoing research on hair color reversal. The treatment showed high efficacy in restoring hair color in trials with 40 to 50 people.

A 26-year-old male considering a hair transplant is using topical finasteride and minoxidil, planning to start feminizing hormone replacement therapy (HRT) with estrogen and spironolactone. Many suggest waiting to see the effects of HRT, which may significantly regrow hair, before deciding on a transplant, and recommend adding microneedling and possibly switching to oral treatments for better results.

The conversation provides scientific sources on hair loss treatments like finasteride, minoxidil, and others, aiming to help individuals make informed decisions about their treatment options. It also discusses phytochemicals as alternative treatments due to concerns about side effects from drug-based therapies.

Hair loss treatments like finasteride, minoxidil, and dutasteride are discussed, with some users expressing skepticism about finding a permanent cure. Current treatments are considered effective but not a permanent solution, and there's a call for advanced AI to focus on solving male pattern baldness.

Promising hair loss treatments in 2026 include GT20029, a topical androgen receptor degrader, and VDPHL01, an extended-release oral minoxidil, both offering safer alternatives with fewer side effects. Other treatments like sublingual minoxidil, OND-1, JW0061, TDM-105795, and AMP-303 are also being explored.

Switching from powdered dutasteride to softgel significantly reduced DHT levels, suggesting softgels are more effective due to better bioavailability. Users discuss the ineffectiveness of compounded forms and emphasize the importance of proper formulation for absorption.

Finasteride and minoxidil remain the primary treatments for hair loss, with dutasteride being a more potent alternative. New treatments like VDPHL01 and topical antiandrogens are in development.

People in Canada are using telehealth platforms like Felix, Phoenix, and Essential to access oral minoxidil and finasteride for hair loss treatment. Some users report satisfaction with these services, while others caution about potential side effects or issues with mixing medications.

Minoxidil formulations often use propylene glycol (PG) for stability and effectiveness, but PG-free alternatives like foams and PEG-based solutions can also be effective with less irritation. Concerns exist about the quality of PG-free minoxidil from lesser-known brands, especially from India, due to potential manufacturing issues.

Dutasteride may not work as effectively as finasteride for everyone, with some users experiencing increased shedding or no improvement. Combining treatments like minoxidil with dutasteride or finasteride can help maintain or improve hair growth, but individual results vary.

A 22-year-old started taking finasteride at 20 to combat hair loss, experiencing significant shedding initially but no side effects. Despite challenges in obtaining dutasteride and oral minoxidil in Sweden, the user is content with the current hairline and considering additional treatments like microneedling.

PP405 and JXL069 are confirmed to be the same molecule, leading to disappointment due to poor hair regrowth results. Users express skepticism about the credibility of Pelage and the effectiveness of JXL069.

Dutasteride tablets are considered legitimate and effective, though some users believe gel capsules may be more effective. The conversation discusses the legitimacy of tablets from stop99bald and the differences in bioavailability between tablet and gel forms.

New hair loss treatments like Breezula and a version of Minoxidil for hair regrowth are in advanced trials and may be available in a few years. Clascoterone and other treatments like oral and topical Minoxidil, Finasteride, and Dutasteride are also discussed, with some users experiencing side effects from Finasteride.

A user shared their experience of easily obtaining dutasteride in Italy using an online prescription service, noting the lower cost compared to their home country. They plan to bring back a large supply due to the ease of purchase and lack of strict prescription checks.